UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk

In a report published Friday, SunTrust Robinson Humphrey analyst Amit Hazan initiated coverage on Myriad Genetics (NASDAQ: MYGN ) with a Reduce rating and $17.00 price target. In the report, SunTrust Robinson Humphrey noted, “Our due diligence leads us to believe that the most imminent threat from new competitors for